NASDAQ$ALLO
Allogene Therapeutics Inc. · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Allogene reported financial results for the fourth quarter and full year 2022 and provided a business update.
Allogene Therapeutics reported a net loss of $94.8 million for the fourth quarter of 2022, with $576.5 million in cash, cash equivalents, and investments as of December 31, 2022. The company highlighted progress in its allogeneic CAR T programs, including the initiation of a pivotal Phase 2 trial for ALLO-501A and promising data from its BCMA and CD70 programs.
- Initiated the industry’s first potentially pivotal Phase 2 allogeneic CAR T trial, ALPHA2, in Relapsed/Refractory (R/R) Large B Cell Lymphoma (LBCL).
- Presented data highlighting industry-leading allogeneic CAR T portfolio.
- Ended 2022 with $576 million in cash, cash equivalents and investments.
- ALLO-316 demonstrated promising anti-cancer activity in the subset of nine patients with confirmed CD70-positive RCC from the ongoing Phase 1 TRAVERSE trial
Headline financials
Revenue & EPS history
Allogene · Revenue · Quarterly
$47K
Forward guidance
Allogene expects a decrease in cash, cash equivalents, and investments of approximately $250 million in 2023. Based on current expectation, the Company expects the cash runway to be sufficient to fund operations into 2025. GAAP Operating Expenses are expected to be approximately $350 million, including estimated non-cash stock-based compensation expense of approximately $90 million. These estimates exclude any impact from potential business development activities.
Tailwinds
- Cash runway is expected to be sufficient to fund operations into 2025.
- Company is making large strides toward giving patients back precious time.
- Allogene initiated the industry’s first potentially pivotal Phase 2 allogeneic CAR T trial, ALPHA2, in Relapsed/Refractory (R/R) Large B Cell Lymphoma (LBCL).
- Presented data highlighting industry-leading allogeneic CAR T portfolio.
- ALLO-316 has demonstrated a generally manageable safety profile with no GvHD
Headwinds
- Company expects a decrease in cash, cash equivalents, and investments of approximately $250 million in 2023.
- Gaining access to autologous CAR T therapy and the inevitable wait times associated with manufacturing remain a critical factor for patients.
- Net loss for the fourth quarter of 2022 was $94.8 million.
- ALLO-501A trial will enroll approximately 100 patients who have received at least two prior lines of therapy and have not received prior anti-CD19 therapy.
- TRAVERSE will continue to explore varying cell dose and lymphodepletion regimens, including FC and FCA.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+1.1%
Avg return
Earnings day
-2.7%
Avg return
5 days after
-5.0%
Avg return
30 days after
53%
16 / 30 earnings
Positive
+23.7%
Q3 2023
Best reaction
-11.8%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | -16.0% | -17.7% | |
| Q4 2025 | -2.8% | -13.0% | +10.1% | |
| Q3 2025 | +10.7% | +17.1% | +36.2% | |
| Q1 2025 | -1.8% | -1.8% | +23.4% | |
| Q4 2024 | +2.6% | -10.6% | -23.3% | |
| Q3 2024 | -4.3% | -11.8% | -32.0% | |
| Q2 2024 | -7.5% | -7.5% | -5.5% | |
| Q1 2024 | +7.2% | +0.4% | -6.9% | |
| Q4 2023 | -4.5% | -10.0% | -22.1% | |
| Q3 2023 | +23.7% | +15.9% | -11.0% | |
| Q2 2023 | +7.3% | -11.3% | -15.4% | |
| Q1 2023 | +20.6% | +18.1% | +4.9% | |
| Q4 2022 | +0.2% | -5.4% | -21.5% | |
| Q3 2022 | -9.9% | -14.2% | -10.5% | |
| Q2 2022 | +1.5% | +8.1% | -3.5% | |
| Q1 2022 | +2.3% | -18.9% | -8.0% | |
| Q4 2021 | -4.8% | -5.9% | -0.7% | |
| Q3 2021 | -0.1% | -5.8% | -12.6% | |
| Q2 2021 | +8.2% | +3.2% | +16.1% | |
| Q1 2021 | -0.7% | -1.4% | -19.0% | |
| Q4 2020 | +0.8% | +0.5% | -1.9% | |
| Q3 2020 | -11.8% | -17.5% | -0.4% | |
| Q2 2020 | +0.3% | -0.6% | -10.9% | |
| Q1 2020 | -0.9% | +8.2% | +38.1% | |
| Q4 2019 | +6.1% | +8.1% | -21.7% | |
| Q3 2019 | -10.5% | -5.5% | +2.1% | |
| Q2 2019 | +4.4% | -0.9% | -7.4% | |
| Q1 2019 | -2.1% | -2.5% | -16.5% | |
| Q4 2018 | -4.7% | -9.3% | -5.7% | |
| Q3 2018 | +3.8% | +8.3% | -5.5% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro